AstraZeneca's breast cancer drug camizestrant fails pivotal first-line trial
AstraZeneca announced that its investigational breast cancer drug camizestrant did not meet primary endpoints in a pivotal Phase 3 trial evaluating it as a first-line treatment for advanced disease.
The study compared camizestrant combined with a partner therapy against the standard of care and found the combination did not demonstrate superior efficacy, raising questions about its future development in this indication.
The setback may limit the drug’s potential market and could affect AstraZeneca’s broader oncology pipeline, though the company may explore alternative indications or combination strategies.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that